Logo image of PALI

PALISADE BIO INC (PALI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PALI - US6963894026 - Common Stock

2.28 USD
+0.15 (+7.04%)
Last: 11/24/2025, 8:00:02 PM
2.24 USD
-0.04 (-1.75%)
After Hours: 11/24/2025, 8:00:02 PM
Fundamental Rating

2

PALI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PALI as it has an excellent financial health rating, but there are worries on the profitability. PALI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PALI had negative earnings in the past year.
In the past year PALI has reported a negative cash flow from operations.
In the past 5 years PALI always reported negative net income.
In the past 5 years PALI always reported negative operating cash flow.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PALI's Return On Assets of -132.70% is on the low side compared to the rest of the industry. PALI is outperformed by 82.36% of its industry peers.
With a Return On Equity value of -192.71%, PALI is not doing good in the industry: 66.23% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROIC N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PALI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

7

2. Health

2.1 Basic Checks

PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PALI has more shares outstanding
PALI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PALI has been reduced compared to a year ago.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

PALI has an Altman-Z score of 28.97. This indicates that PALI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PALI (28.97) is better than 93.81% of its industry peers.
PALI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.97
ROIC/WACCN/A
WACC8.7%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
PALI has a worse Current ratio (3.24) than 60.98% of its industry peers.
A Quick Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
PALI has a Quick ratio (3.24) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

PALI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.15%, which is quite impressive.
The Revenue for PALI has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.95% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.01%
EPS Next 2Y39.06%
EPS Next 3Y23.86%
EPS Next 5Y13.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2028 2029 2030 2031 2032 100M 200M 300M 400M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100K -200K -300K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PALI's earnings are expected to grow with 23.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.06%
EPS Next 3Y23.86%

More info and screens

0

5. Dividend

5.1 Amount

PALI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALISADE BIO INC

NASDAQ:PALI (11/24/2025, 8:00:02 PM)

After market: 2.24 -0.04 (-1.75%)

2.28

+0.15 (+7.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners0.96%
Inst Owner Change13.82%
Ins Owners0.25%
Ins Owner Change0%
Market Cap303.24M
Revenue(TTM)N/A
Net Income(TTM)-14.44M
Analysts84.44
Price Target11.9 (421.93%)
Short Float %6.28%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.91%
Min EPS beat(2)23.66%
Max EPS beat(2)32.15%
EPS beat(4)3
Avg EPS beat(4)12.73%
Min EPS beat(4)-11.13%
Max EPS beat(4)32.15%
EPS beat(8)4
Avg EPS beat(8)3.92%
EPS beat(12)8
Avg EPS beat(12)37.63%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)45.83%
PT rev (3m)45.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)12.89%
EPS NY rev (3m)12.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 40.48
P/tB 40.48
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.24
Quick Ratio 3.24
Altman-Z 28.97
F-Score2
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)144.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.62%
EPS Next Y87.01%
EPS Next 2Y39.06%
EPS Next 3Y23.86%
EPS Next 5Y13.95%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.52%
OCF growth 3YN/A
OCF growth 5YN/A

PALISADE BIO INC / PALI FAQ

Can you provide the ChartMill fundamental rating for PALISADE BIO INC?

ChartMill assigns a fundamental rating of 2 / 10 to PALI.


What is the valuation status for PALI stock?

ChartMill assigns a valuation rating of 1 / 10 to PALISADE BIO INC (PALI). This can be considered as Overvalued.


How profitable is PALISADE BIO INC (PALI) stock?

PALISADE BIO INC (PALI) has a profitability rating of 0 / 10.


Can you provide the financial health for PALI stock?

The financial health rating of PALISADE BIO INC (PALI) is 7 / 10.